Verana Health

CASE STUDY | ARVO 2026 | AMERICAN ACADEMY OF OPHTHALMOLOGY

Enabling patient identification and genetic testing for rare RPGR-mutated XLRP patients to accelerate trial recruitment

Gene therapy candidate developed under a Janssen and MeriaGTx collaboration for XLRP was presented at American Academy of Ophthalmology and ARVO conferences.

Background

- X-linked Retinitis Pigmentosa (XLRP) is a rare inherited photoreceptor dystrophy.
- Sponsor was looking to enroll more patients in their Phase III study for a gene therapy.

Methods

Enable patient identification at practices, refer patients for genetic testing and counseling, then refer to trial sites to accelerate recruitment.

Results

Verana Health was able to identify practices with potentially eligible patients and refer 14 who were previously invisible to sponsor.

Algorithm Development
46,000
Patients identified with suspect retinitis pigmentosa

Site Otreach & Onboarding
60+
Sites onboarded

Genetic Testing & Counseling
87
Patients completed genetic testing and counseling

Referred to Site
14
Rare mutation patients identified, 9 referred

As of May 2022 Sources: Phase 1/2 AAV5-RPGR (Botaretigene Sparoparvovec) Gene Therapy Trial in RPGR-Associated X-linked Retinitis Pigmentosa. American Academy of Ophthalmology (AAO), 2022 Safety and Visual Function Outcomes Following Subretinal AAV5-RPGR (Botaretigene Sparoparvovec) Delivery in XLRP. Association for Research in Vision and Ophthalmology (AVRO), 2023